SEOM clinical guidelines in metastatic breast cancer 2015

被引：0
作者：
J. Gavilá
S. Lopez-Tarruella
C. Saura
M. Muñoz
M. Oliveira
L. De la Cruz-Merino
S. Morales
I. Alvarez
J. A. Virizuela
M. Martin
机构：
[1] Fundación Instituto Valenciano de Oncología,Servicio de Oncología Médica
[2] Hospital General Universitario Gregorio Marañón,Servicio de Oncología Médica
[3] Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM),Servicio de Oncología Médica
[4] Hospital Vall d’ Hebron,Servicio de Oncología Médica
[5] Hospital Clinic I Provincial,Servicio de Oncología Médica
[6] Complejo Hospitalario Regional Virgen Macarena,Servicio de Oncología Médica
[7] Hospital Universitari Arnau de Villanova de Lleida,Servicio de Oncología Médica
[8] Hospital Donostia-Donostia Ospitalea,Instituto de Investigación Sanitaria Gregorio Marañón
[9] Universidad Complutense,undefined
来源：
Clinical and Translational Oncology | 2015年 / 17卷
关键词：
Metastatic breast cancer; Clinical guidelines; Chemotherapy; Hormonal therapy; Anti-HER2 therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Metastatic breast cancer is essentially an incurable disease. However, recent advances have resulted in a significant improvement of overall survival. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with metastatic breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference.
引用
收藏
页码：946 / 955
页数：9
相关论文
共 211 条
  • [1] Largillier R(2008)Prognostic factors in 1038 women with metastatic breast cancer Ann Oncol 19 2012-2019
  • [2] Ferrero J-M(2014)Clinical application of 18F-fluoro-2-deoxy- Clin Physiol Funct Imaging 34 426-433
  • [3] Doyen J(2012)-glucose positron emission tomography/computed tomography in breast cancer Clin Cancer Res Off J Am Assoc Cancer Res. 18 5701-5710
  • [4] Barriere J(2014)Meta-analysis of the prognostic value of circulating tumor cells in breast cancer Breast Cancer Res Treat 143 507-515
  • [5] Namer M(2012)Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009–03 ConvertHER study Ann Oncol Off J Eur Soc Med Oncol ESMO. 23 x349-x353
  • [6] Mari V(2011)When to order a biopsy to characterise a metastatic relapse in breast cancer Breast Cancer Res Treat 129 659-674
  • [7] Bernsdorf M(2010)HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis Clin Oncol R Coll Radiol G B. 22 818-827
  • [8] Graff J(2001)Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients N Engl J Med 344 783-792
  • [9] Zhang L(2012)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 Breast. 21 27-33
  • [10] Riethdorf S(2009)Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer—results of the eLEcTRA trial J Clin Oncol 27 5538-5546
12345678910